STOCK TITAN

Eloxx Pharmaceuticals (ELOX) grants director 8,590 stock options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Eloxx Pharmaceuticals director Alan Edmund Walts received a grant of 8,590 stock options to buy common stock. The options have an exercise price of $11.00 per share and expire on June 8, 2036. They vest in 24 substantially equal monthly installments, becoming fully exercisable on the second anniversary of the grant date, as long as he continues to serve the company. Following this award, he holds 8,590 stock options directly, and the filing does not show any open-market purchases or sales.

Positive

  • None.

Negative

  • None.
Insider Walts Alan Edmund
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 8,590 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 8,590 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Options granted 8,590 options Stock Option (Right to Buy) granted to director on June 8, 2026
Exercise price $11.00 per share Conversion or exercise price of granted stock options
Expiration date June 8, 2036 Options expire on this date
Underlying shares 8,590 shares Common stock underlying the stock options
Total options after grant 8,590 options Total derivative securities held following transaction
Vesting schedule 24 monthly installments Options fully vest by second anniversary of grant date
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 11.0000"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-06-08T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
Common Stock financial
"underlying_security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
Grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
vesting financial
"The stock option will vest in 24 substantially equal monthly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Walts Alan Edmund

(Last)(First)(Middle)
C/O ELOXX PHARMACEUTICALS, INC.
P.O. BOX 274

(Street)
ARLINGTON MASSACHUSETTS 02476

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Eloxx Pharmaceuticals, Inc. [ ELOX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/08/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$1106/08/2026A8,590 (1)06/08/2036Common Stock8,590$08,590D
Explanation of Responses:
1. The stock option will vest in 24 substantially equal monthly installments so that the option will be fully vested and exercisable on the second anniversary of the grant date, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date.
/s/ Sumit Aggarwal, Attorney-in-Fact06/10/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Eloxx Pharmaceuticals (ELOX) disclose in this Form 4 filing?

Eloxx Pharmaceuticals disclosed that director Alan Edmund Walts received a grant of 8,590 stock options. These options give him the right to buy common shares at $11.00 each, expiring June 8, 2036, with vesting over two years.

How many stock options did Alan Edmund Walts receive from Eloxx Pharmaceuticals (ELOX)?

Alan Edmund Walts received 8,590 stock options as reported in the Form 4. Each option represents the right to purchase one share of Eloxx common stock, subject to vesting conditions and the $11.00 exercise price.

What is the exercise price and expiration date of the ELOX options granted to Alan Walts?

The options granted to Alan Walts have an exercise price of $11.00 per share and expire on June 8, 2036. This means he can buy Eloxx common shares at $11.00 any time after vesting until that expiration date.

How do the Eloxx Pharmaceuticals (ELOX) options granted to Alan Walts vest?

The options vest in 24 substantially equal monthly installments starting from the grant date. They become fully vested and exercisable on the second anniversary of the grant, provided Alan Walts maintains continuous service with Eloxx through each vesting date.

Did Alan Edmund Walts buy or sell any Eloxx (ELOX) shares in the market in this Form 4?

The Form 4 shows a grant of 8,590 stock options to Alan Edmund Walts, not an open-market trade. It reports a compensation-related award at a $11.00 exercise price, with no market purchases or sales disclosed in this filing.

How many Eloxx Pharmaceuticals options does Alan Walts hold after this grant?

After the reported grant, Alan Walts holds 8,590 stock options directly, as shown by the total shares following the transaction. These options relate to Eloxx common stock and are subject to the stated vesting and expiration terms.